Business Wire

NielsenIQ (NIQ) Unleashes the Power of a Connected User Experience With Consumer Panel and Retail Measurement Data Integrated on the NIQ Discover Platform

10.7.2024 16:00:00 EEST | Business Wire | Press release

Share

NielsenIQ (NIQ) today announced the launch of an integrated user experience for its Consumer Panel clients globally. This brings the Full View of Retail measurement and Consumer Panel data to life on a single platform, NIQ Discover. With a focus on elevating the client experience, the Discover platform leverages a new cloud-based architecture and aggregation engine providing faster data accessibility and user flexibility.

NIQ's Discover platform for Consumer Panel is set to transform the consumer insights landscape. With its advanced analytical models and always-on capabilities, NIQ is leading the way in delivering actionable insights. Clients can now enjoy a modern and intuitive interface that enhances their interaction with the platform, opening endless possibilities to analyze consumer behaviors to drive growth. “NIQ has made significant investments in our global consumer panel capabilities in the past year, enhancing performance, quality and usability of data driven insights. The launch of this modern, cloud-based platform is one of several enhancements we are making to our Consumer Panel offerings globally. Clients will now get access to panel data together with retail measurement, delivering a connected user experience,” said Kris Ewing, President, Global Consumer Panel Services, NIQ.

Key benefits of NIQ Discover platform for Consumer Panel include:

  • Elevated user experience: On-demand insights unlocked through an intuitive and powerful visualization experience, side-by-side with retail measurement data, enabling seamless, guided flows that cross complementary data sets.
  • Flexibility: Clients can build their own analyses and get results on-the-fly, opening a world of possibilities across different dimensions of people groups, facts, products, retailers, geographies, periods and demographics.
  • On-demand Data: Access to advanced analytical models elevates the data analysis experience seamlessly within seconds. Clients can access key performance indicators like penetration in addition to more sophisticated analytical models like Super Shifting, Key Item Ranking, Assortment Optimizer and Portfolio Trial and Repeat
  • Gen AI-driven insights through NIQ Ask Arthur: Consumer panel on NIQ Discover enables users to leverage NIQ Ask Arthur, a groundbreaking Gen AI-driven tool, to aid in global search, streamline data analysis and facilitate informed decision-making.

NIQ’s Consumer Panel Services (CPS) provides the most complete and clear view of today’s consumers across 23 markets. Some of the enhancements NIQ is making to its Consumer Panel include:

  • Expansion of panel sample sizes globally, with broader coverage and representation across North America, West Europe, and Pacific.
  • The best data: Delivering the Full View of consumer behavior across retail channels and brands with panel quality and coverage the industry trusts.​
  • Expanded analytical capacity through industry-leading consumer experts who bring powerful insights to life, connecting NIQ’s Retail Measurement data, Consumer Panel and other NIQ offerings to drive growth for CPG and retailer clients.

NIQ Discover for CPS provides an unparalleled user experience, delivering the best quality, the widest coverage, and most sophisticated analytics all in a single platform. It redefines the way clients can harness the analytical power of NIQ data and elevate insights to unprecedented heights.

About NIQ

NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710255063/en/

Contacts

sweta.patra@nielseniq.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye